Inhibition of chemokine (C-C Motif) receptor 7 sialylation suppresses CCL19-stimulated proliferation, invasion and anti-anoikis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Su, Mei Lin ^a   Chang, Tsung Ming ^b   Chiang, Chi Hsiang ^b   Chang, Han Chen ^e   Hou, Ming Feng ^c,d   Li, Wen Shan ^e   Hung, Wen Chun ^a,b  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e INSTITUTE OF CHEMISTRY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AL 10; ALPHA 2,3 SIALYLTRANSFERASE; CHEMOKINE RECEPTOR CCR7; ENZYME INHIBITOR; LECTIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; REGULATOR PROTEIN; SIALIDASE; SIALYLTRANSFERASE; SIALYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASE; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOIKIS; ARTICLE; BIOLOGICAL FUNCTIONS; BREAST CANCER; CANCER CELL; CANCER CELL LINE; CANCER THERAPY; CANCER TISSUE; CARCINOGENICITY; CATALYSIS; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; EXPERIMENTAL ANIMAL; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PARACRINE SIGNALING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIALYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BREAST TUMOR; CELL LINE; CELL MOTION; CELL TRANSFORMATION; DISEASE MODEL; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; RNA PROCESSING; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANOIKIS; BREAST NEOPLASMS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINE CCL19; CYCLIN D1; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION; GLYCOGEN SYNTHASE KINASE 3; HETEROGRAFTS; HUMANS; RECEPTORS, CCR7; RNA PROCESSING, POST-TRANSCRIPTIONAL; SIALYLTRANSFERASES; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84902590692     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098823     Document Type: Article

References (43)

1. Spiro RG (2002) Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12: 43R-56R.
2. Schauer R (2009) Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 19: 507-514.
3. Angata T, Varki A (2002) Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective. Chem Rev 102: 439-469. (Pubitemid 35381636)
4. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, et al. (2001) The human sialyltransferase family. Biochimie 83: 727-737. (Pubitemid 32821237)
5. Varki NM, Varki A (2007) Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 87: 851-857. (Pubitemid 47267816)
6. Pshezhetsky AV, Ashmarina LI (2013) Desialylation of surface receptors as a new dimension in cell signaling. Biochemistry 78: 736-745.
7. Crespo HJ, Lau JT, Videira PA (2013) Dendritic Cells: A Spot on Sialic Acid. Front Immunol 4: 491.
8. Schedin-Weiss S, Winblad B, Tjernberg LO (2014) The role of protein glycosylation in Alzheimer disease. FEBS J 281: 46-62.
9. Maguire TM, Gillian AM, O'Mahony D, Coughlan CM, Dennihan A, et al. (1994) A decrease in serum sialyltransferase levels in Alzheimer's disease. Neurobiol Aging 15: 99-102. (Pubitemid 24075017)
10. Fodero LR, Saez-Valero J, Barquero MS, Marcos A, McLean CA, et al. (2001) Wheat germ agglutinin-binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid. J Neurochem 79: 1022-1026. (Pubitemid 33117081)
11. Ohtsubo K, Marth JD (2006) Glycosylation in cellular mechanisms of health and disease. Cell 126: 855-867. (Pubitemid 44310784)
12. Park JJ, Yi JY, Jin YB, Lee YJ, Lee JS, et al. (2012) Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells. Biochem Pharmacol 83: 849-857.
13. Swindall AF, Bellis SL (2011) Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. The J Biol Chem 286: 22982-22990.
14. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N (2004) Carbohydratemediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 95: 377-384. (Pubitemid 38832679)
15. Chiang CH, Wang CH, Chang HC, More SV, Li WS, et al. (2010) A novel sialyltransferase inhibitor AL10 suppresses invasion and metastasis of lung cancer cells by inhibiting integrin-mediated signaling. J Cell Physiol 223: 492-499.
16. Schneider F, Kemmner W, Haensch W, Franke G, Gretschel S, et al. (2001) Overexpression of sialyltransferase CMP-sialic acid:Galbeta1, 3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas. Cancer Res 61: 4605-4611. (Pubitemid 32685796)
17. Hedlund M, Ng E, Varki A, Varki NM (2008) alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 68: 388-394. (Pubitemid 351380065)
18. Muller A, Homey B, Soto H, Ge N, Catron D, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56. (Pubitemid 32225831)
19. Pan MR, Hou MF, Chang HC, Hung WC (2008) Cyclooxygenase-2 upregulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem 283: 11155-11163.
20. Chuang CW, Pan MR, Hou MF, Hung WC (2013) Cyclooxygenase-2 upregulates CCR7 expression via AKT-mediated phosphorylation and activation of Sp1 in breast cancer cells. J Cell Physiol 228: 341-348.
21. Bannert N, Craig S, Farzan M, Sogah D, Santo NV, et al. (2001) Sialylated Oglycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines. J Exp Med 194: 1661-1673. (Pubitemid 33126816)
22. Frommhold D, Ludwig A, Bixel MG, Zarbock A, Babushkina I, et al. (2008) Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation. J Exp Med 205: 1435-1446. (Pubitemid 351831498)
23. Hsu MC, Chai CY, Hou MF, Chang HC, Chen WT, et al. (2008) Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu. Mod Pathol 21: 609-616.
24. Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, et al. (2010) Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology 20: 1241-1250.
25. Cui H, Lin Y, Yue L, Zhao X, Liu J (2011) Differential expression of the alpha2, 3-sialic acid residues in breast cancer is associated with metastatic potential. Oncol Rep 25: 1365-1371.
26. Riol-Blanco L, Sanchez-Sanchez N, Torres A, Tejedor A, Narumiya S, et al. (2005) The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J Immunol 174: 4070-4080. (Pubitemid 40395983)
27. Xu Y, Liu L, Qiu X, Liu Z, Li H, et al. (2012) CCL21/CCR7 prevents apoptosis via the ERK pathway in human non-small cell lung cancer cells. PLoS One 7: e33262.
28. Shannon LA, Calloway PA, Welch TP, Vines CM (2010) CCR7/CCL21 migration on fibronectin is mediated by phospholipase Cgamma1 and ERK1/2 in primary T lymphocytes. J Biol Chem 285: 38781-38787.
29. Zhou F, Cui C, Ge Y, Chen H, Li Q, et al. (2010) Alpha2, 3-Sialylation regulates the stability of stem cell marker CD133. J Biochem 148: 273-280.
30. de Laurentiis A, Gaspari M, Palmieri C, Falcone C, Iaccino E, et al. (2011) Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein. Mol Cell Proteomics 10: M111.007898.
31. Ma H, Zhou H, Song X, Shi S, Zhang J, et al. (2014) Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene doi:10.1038/onc.2014.7.
32. Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511. (Pubitemid 28553242)
33. Diehl JA, Zindy F, Sherr CJ (1997) Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11: 957-972. (Pubitemid 27199876)
34. Alt JR, Cleveland JL, Hannink M, Diehl JA (2000) Phosphorylation- dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14: 3102-3114. (Pubitemid 32015129)
35. Zou Y, Ewton DZ, Deng X, Mercer SE, Friedman E (2004) Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem 279: 27790-27798. (Pubitemid 38812621)
36. Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24.
37. Vaites LP, Lee EK, Lian Z, Barbash O, Roy D, et al. (2011) The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation. Mol Cell Biol 31: 4513-4523.
38. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, et al. (2006) A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One 1: e128.
39. Feng Q, Sekula D, Muller R, Freemantle SJ, Dmitrovsky E (2007) Uncovering residues that regulate cyclin D1 proteasomal degradation. Oncogene 26: 5098-5106. (Pubitemid 47206943)
40. Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23: 4215-4224. (Pubitemid 46211327)
41. Roy PG, Thompson AM (2006) Cyclin D1 and breast cancer. Breast 15: 718-727. (Pubitemid 44774238)
42. Kilker RL, Hartl MW, Rutherford TM, Planas-Silva MD (2004) Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. J Steroid Biochem Mol Biol 92: 63-71. (Pubitemid 39486063)
43. Kilker RL, Planas-Silva MD (2006) Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. Cancer Res 66: 11478-11484. (Pubitemid 46009981)